StemRIM is a Japanese biotechnology company developing regeneration-inducing medicines that recruit and activate a patient's own mesenchymal stem cells to repair damaged tissues
StemRIM is a Japanese biotechnology company developing regeneration-inducing medicines that recruit and activate a patient's own mesenchymal stem cells to repair damaged tissues. Its pipeline includes chemically synthesized peptide therapeutics for conditions such as epidermolysis bullosa, stroke, myocardial infarction and cardiomyopathy, as well as autologous stem-cell gene therapy for epidermolysis bullosa.